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Abstract - Atrial fibrillation (AF) is the most common 
cardiac arrhythmia, occurring in 1-2% of overall 
population, involving more than 6 millions of 
European people. It  is associated to a reduced quality 
of life and an increased morbidity and mortality. The 
Framingham study showed the link between angina 
and AF. The same risk factors, such as hypertension, 
diabetes and obesity promote both AF and coronary 
artery disease (CAD). About 1/4 of AF patients 
develop a CAD and, in this setting, about 1/5 
undergoes a percutaneous coronary intervention (PCI). 
In patients with both AF and CAD, the optimal medical 
strategy is challenging and it is still debated in 
cardiological community, since patients treated by dual 
(two antiplatelets drugs ore one antiplatelets drug and 
an oral anticoagulant drug) or triple therapy (two 
antiplatelets drugs and an oral anticoagulant drug) are 
exposed to divergent risk of bleeding or 
thromboembolic and ischemic complications.  
Aim of this paper is to focus the attention on the 
different problems arising from the presence of  AF in 
patients undergoing PCI, such as the risk of stroke, 
bleeding and stent thrombosis. 
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Atrial fibrillation (AF) is the most common cardiac 
arrhythmia, occurring in 1-2% of overall population, 
involving more than 6 millions of European people [1]. 
AF is associated to a reduced quality of life and an 
increased morbidity and mortality, due to its not 
uncommon complications, such as arterial embolism 
[2,3]. Furthermore, AF development after an acute 
coronary syndrome is related with a worse prognosis 
[4]. The Framingham study showed the link between 
angina and AF, especially in males [5-7]. Both AF and 
coronary artery disease (CAD) are occurring in 
presence of  similar risk factors, such as hypertension, 
diabetes and obesity. In AF patients the average CAD 
incidence is 34%, according to the different study 
populations,  reaching more than 40% in patients older 
than 70 years [8]. Among all this patients about 1/5 
undergoes a percutaneous coronary intervention (PCI), 
opening a controversy about the optimal antiplatelet 
medical strategy [8]. In patients with concomitant 
coronary artery disease and AF, the optimal medical 
strategy is challenging, since patients treated by dual 
(two antiplatelets drugs or one antiplatelets drug and an 
oral anticoagulant drug) or triple therapy (two 
antiplatelets drugs and an oral anticoagulant drug) are 
exposed to divergent risk of bleeding or 
thromboembolic and ischemic complications.  
Aim of this paper is to focus the attention on the 
different problems arising from the presence of  AF in 
patients undergoing PCI, such as the risk of stroke, 
bleeding and stent thrombosis.  
 
II. RISK STRATIFICATION 
 
According to the current guidelines of the European 
Society of Cardiology (ESC) for AF oral 
anticoagulation should be started after risk 
stratification [1]. The most commonly used stroke risk 
score in clinical practice is the CHA2DS2-Vasc-Score; 
it consists of eight different clinical and anamnestic 
parameters with the attribution of one point per each, 
with exception of  age ≥ 75 years and previous stroke 
or thrombo-embolism (attribution of 2 points). Oral 
anticoagulation is indicated when the  CHA2DS2-
Vasc-Score is ≥ 2. The superiority of oral 
anticoagulation compared to antiplatelet therapy in 
prevention of thromboembolism in patients with atrial 
fibrillation has been already demonstrated [9]. 
Therefore, not all AF patients need to be treated by oral 
anticoagulation, but only those with an elevated 
embolic risk. The patients at low embolic risk should 
be treated by using aspirin alone; unfortunately the rate 
of this low risk patients is less than 10% [1]. On the 
other hand a more aggressive antiplatelet strategy 
correlates with an increased bleeding risk, that should 
be evaluated by using an haemorrhagic risk score, such 
as the HAS-BLED-Score. However some clinical 
variables are common in both embolic and 
haemorrhagic risk score, leading to a very challenging 
appropriate medical therapy. 
 
III. ANTIPLATELET THERAPY AFTER 
STENT IMPLANTATION 
 
According to ESC guidelines on myocardial 
revascularization, the dual antiplatelet therapy (DAPT) 
should be performed 1 month after bare metal stent 
(BMS) implantation in stable angina, 6-12 months after 
drug eluting stent (DES) implantation in all patients, 
and 12 months in all patients after acute coronary 
syndrome irrespectively of revascularization strategy 
[10]. By using risk score stratification a triple therapy 
consisting of a vitamin-K-antagonist, aspirin, and 
clopidogrel is recommended in all patients with an 
higher embolic risk. Depending on the clinical setting 
(acute coronary syndrome or stable angina), 
hemorrhagic and stroke risk, and the type of stent 
implanted, triple therapy should be prescribed for the 
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shortest  time possible,  continuing with a vitamin-K-
antagonist alone administration as lifelong therapy.  
Others oral antiplatelets drugs, such as Prasugrel and 
Ticagrelor, are now commercially available to prevent 
reinfarction and stent thrombosis. The comparison in 
terms of efficacy and adverse events between 
Clopidogrel vs Prasugrel and Clopidogrel vs Ticaglelor 
has been performed in TRITON-TIMI 38 and PLATO 
studies, respectively. By using Prasugrel as well as 
Ticagrelor the platelets activity inhibition is faster and 
more effective. Unfortunately the higher efficacy of 
Prasugrel in platelets inhibition activity correlates to an 
higher rate of life threatening bleedings (1.4% vs. 
0.9%; p = 0.01). Conversely, in PLATO trial no 
statistically significant increase of major bleeding has 
been reported (11.6% with Ticagrelor vs 11.2% with 
Clopidogrel; p = n.s.) [11, 12].  
Despite the superior efficacy of these new antiplatelets 
drugs, we do not have data on their association with 
vitamin-K-antagonist, available in AF patients who 
underwent  PCI. The major risk of bleeding carried out 
by these new drugs makes them potentially harmful in 
association with vitamin-K-antagonist. Thus dedicated 
randomized trials and or registries are needed in order 
to demonstrate their efficacy and safety in this 
particular clinical setting.  
 
IV. PROBLEMS IN TRIPLE ANTIPLATELET 
THERAPY 
 
Stroke, bleeding and stent thrombosis are different 
aspects of the same phenomenon. An aggressive 
antiplatelet strategy (oral anticoagulation, OAC, + 
DAPT) leads to an increased bleeding risk, conversely 
a conservative antiplatelet strategy (OAC + single 
antiplatelet therapy, SAPT) leads to an increased 
embolic risk and an increased stent thrombosis rate 
[13]. In 239 patients treated by SAPT, comparing 
efficacy and safety of OAC + Aspirin vs OAC + 
Clopidogrel at 12 months, the first group showed a 
lower incidence of major bleedings and an higher 
incidence of stent thrombosis (6,1 vs 11,1% and 15,2 
vs 0%, respectively) [14]. According to a consensus 
document of the European Society of Cardiology AF 
patients, with moderate to high stroke risk, undergoing  
PCI should be treated by triple therapy (TT), consisting 
in oral anticoagulation, aspirin and clopidogrel after 
stent implantation, preferably a BMS [15]. 
Nevertheless the major bleedings rate increase during 
the first 12 months, irrespective of the type of stent  
implanted  [16].  
Despite guidelines recommendations, in clinical 
practice the duration of DAPT after PCI depends from 
the type of stent used, 1 month for a BMS and 12 
months for a DES, respectively [17]. 
 
V. DES AND BMS, WHICH STENT FOR 
WHICH PATIENT 
 
Thus, what is the best management in AF patient  
undergoing  PCI? 
− Appropriate bleeding and embolic risk 
stratification should be performed. 
− Radial approach should be preferred, due to its 
lower incidence of bleeding complications [18].  
− INR therapeutic range should be lower, between 
2.0-2.5 [19].  
− Gastric protection with either protonic pump 
inhibitors, H2-receptor antagonists or antiacid 
drugs is recommended [15].  
− TT should be performed as less as possible.  
According to a consensus document of the European 
Society of Cardiology, in AF patients requiring a stent 
implantation BMS should be preferred, restricting DES 
implantation in few clinical and/or anatomical 
situations, such as age < 75 years, long lesions, small 
vessels, diabetes, etc, in which DES have  shown a 
better performance than BMS [15]. In case of DES 
implantation, a second generation DES should be 
preferred, such as a tacrolimus eluting stent, a 
Carbostent polymer-free stent, which requires DAPT 
only for two months, as reported from the MATRIX 
study, in 572 patients [20]. Conversely, if an 
everolimus and zotarolimus eluting stent has been 
implanted, DAPT could be discontinued after 3 months 
without an increasing rate of stent thrombosis, as 
observed in more than 6800 patients and more than 
2200 patients, respectively [21,22]. In case of BMS 
implantation a last generation of BMS should be used. 
The preferred stent used should be Genous stent, 
requiring only 15 days of DAPT, due to its anti-hCD34 
coating, which allows an accelerated re-endothelization 
by capturing circulating CD34+ endothelial progenitor 
cells [23, 24]. This peculiar aspect has been reported in 
384 patients enrolled in the ARGENTO study, 
validating the safety of this very short time of DAPT 
[24]. Another possibility is represented by the 
Avantgarde stent, which requires less than one month 
DAPT, due to its peculiar projected design, favoring a 
better endothelization. This stent was evaluated in 42 
patients requiring coronary revascularization before an 
undeferrable major non-cardiac surgery, performed 27 
± 9 days after PCI. Only one major cardiac adverse 
event was observed at one month follow-up [25]. 
Finally, in STEMI setting with angiographic evidence 
of thrombus a bare metal  MGuard stent should be 
implanted. MGuard stent has been evaluated in 150 
patients undergoing primary or rescue PCI; its ability 
to dramatically reduce distal thrombus embolization 
led to a TIMI flow grade 2.85 ± 0.40 and a myocardial 
blush grade 3 of 90%. Furthermore, within 30 minutes  
after the procedure a very  high rate of complete (> or 
= 70%) ST-segment resolution (90%)  was observed 
[26, 27].   
Independently of the implanted stent, as suggested by 
the current guidelines, the radial approach should be 
preferred in order to its lower incidence of bleeding 
complications, as already demonstrated by several 
meta-analyses [28, 29]. Romagnoli et al. in a recently 
published randomized controlled trial, comparing  
radial versus femoral approach in ST-elevated 
myocardial infarction patients who underwent primary 
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PCI, showed a significant reduction of major adverse 
cardiac events in the radial arm of the study [30].  
However, the great enthusiasm coming from clinical 
trials data seems to be questioned by recent data 
reanalysis [31, 32]. Thus this increased enthusiasm 
about radial approach might be owed more to the 
patients and interventional cardiologist preferences, 
than to a true mortality rate reduction. 
 
VI. NEW ORAL ANTICOAGULANT 
AGENTS 
 
New anticoagulant drugs are safe and effective 
compared to warfarin in non-valvular AF patient. The 
use of these new anticoagulant drugs is still a matter of 
debate due to the controversial results observed in the 
different clinical trials in this particular setting. 
Compared with placebo, the apixaban addiction to 
DAPT, in treatment of non-valvular AF after acute 
coronary syndrome occurrence, leads to an increased 
rate of bleedings, with no better thromboembolic 
outcomes [33].  
Conversely a very-low dosage of rivaroxaban, used in 
acute coronary patients setting, showed the reduction 
of thromboembolic complications with an increasing 
rate of nonfatal bleedings [34]. A substudy of the RE-
LY trial, showed an increased bleeding risk in 
dabigatran addiction to DAPT compared to SAPT [35]. 
On this ground, further studies are strongly needed in 
order to evaluate the efficacy and the safety of these 
new drugs in association with either old and new 
antiplatelets drugs.  
 
VII.   CONCLUSIONS 
 
AF and CAD are strictly related. An individualized 
approach with a tailored medical and interventional 
strategy is required in  patients with concomitant AF 
and CAD, in order to obtain a  balance between the risk 
of cerebrovascular events, bleeding complications and 
reinfarction rate. In short time TT benefits are superior 
to its side effects, nevertheless  it should be prolonged 




Figure 1. Flowchart management of atrial fibrillation 
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